Eikon Therapeutics Debuts on Nasdaq with Over 5% Opening Decline

Stock News

Feb 06

On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel laureates in chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian and is currently developing multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is undergoing mid-to-late stage clinical trials for skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from the study is expected to be released in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1169632829"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169632829\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169632829?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 01:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169632829","market":"fut","top_or_hot":-1,"title":"Eikon Therapeutics Debuts on Nasdaq with Over 5% Opening Decline","media":"Stock News","content":"<p>On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel laureates in chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian and is currently developing multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is undergoing mid-to-late stage clinical trials for skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from the study is expected to be released in the second half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eikon Therapeutics Debuts on Nasdaq with Over 5% Opening Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEikon Therapeutics Debuts on Nasdaq with Over 5% Opening Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-06 01:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel laureates in chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian and is currently developing multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is undergoing mid-to-late stage clinical trials for skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from the study is expected to be released in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QQQ","symbol_name":"纳指100ETF","start_time":0,"source_url":"","article_id":"1169632829","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169632829","pubTimestamp":1770313654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QQQ":"纳指100ETF","TZA":"罗素2000指数三倍做空ETF","QYLD":"纳斯达克100 Covered Call ETF-Global X","IWN":"罗素2000价值股指数ETF-iShares","BK4535":"淡马锡持仓","IWO":"罗素2000成长股指数ETF","TWM":"罗素2000指数两倍做空ETF","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","QLD":"2倍做多纳斯达克100指数ETF-ProShares","QYLG":"Nasdaq 100 Covered Call & Growth ETF","SRTY":"罗素2000指数三倍做空ETF-ProShares","BK4588":"碎股","USJW.SI":"ALPHAB 3xLongSG261006","TSYW.SI":"TESLA 3xLongSG261006","BK4550":"红杉资本持仓","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","SQQQ":"纳指三倍做空ETF","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","BK4007":"制药","RWM":"罗素2000指数反向ETF","NVIW.SI":"NVDA 3xLongSG261006","BK4539":"次新股","QID":"两倍做空纳斯达克指数ETF-ProShares","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","BK4581":"高盛持仓","PSQ":"做空纳斯达克100指数ETF-ProShares","QQQM":"NASDAQ100指数ETF-Invesco","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","USAW.SI":"AMZN 3xLongSG261006","TQQQ":"纳指三倍做多ETF","BK4585":"ETF&股票定投概念","EIKN":"Eikon Therapeutics","BK1147":"投资银行业与经纪业","BK4534":"瑞士信贷持仓","UWM":"罗素2000指数ETF两倍做多","BK4139":"生物科技","TNA":"罗素2000指数三倍做多ETF-Direxion"},"translate_title":"Eikon Therapeutics在纳斯达克首次亮相，开盘跌幅超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPIQ":1,"TNA":1,"TZA":1,"QQQE":1,"IWN":1,"QQQ":1,"USAW.SI":1,"UWM":1,"PSQ":1,"QYLD":1,"RWM":1,"QQQY":1,"EIKN":1,"USJW.SI":1,"MNQmain":1,"NVIW.SI":1,"QLD":1,"TQQQ":1,"IWO":1,"QYLG":1,"TSYW.SI":1,"QQQJ":1,"TWM":1,"QID":1,"SRTY":1,"SQQQ":1,"QQQM":1,"JEPQ":1},"content_text":"On Thursday, Eikon Therapeutics (EIKN.US) began trading on the Nasdaq exchange, opening more than 5% lower at $17.05 per share, below its IPO price of $18. The company was founded in 2019 by Nobel laureates in chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian and is currently developing multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is undergoing mid-to-late stage clinical trials for skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from the study is expected to be released in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}